AltamarCAM Partners, an independent private markets asset manager with more than €22 billion of investor commitments, has reached an agreement with Cleon Capital to lead the replacement of several family offices, including Spanish investors, that had held a minority stake in Italian nutraceutical company Labomar since 2020, while also injecting additional capital into the project.
Through this transaction, AltamarCAM Partners joins a group of institutional investors and international high-net-worth individuals backing projects led by Cleon Capital in Spain and Italy. The partnership strengthens AltamarCAM’s access to direct investments in mid-sized Italian companies through Cleon Capital, which benefits from a local presence and a strong network of contacts and investors across Italy.
Labomar: innovation and growth in the nutraceutical sector
Labomar is an Italian company generating revenues of more than €140 million, specializing in the development and production of advanced, tailor-made nutraceutical solutions. Its offering spans the entire value chain, from R&D to industrial manufacturing of dietary supplements, medical devices, cosmetics, and foods for special medical purposes, ensuring safe, effective, and differentiated products.
Over the last five years, Labomar has tripled its revenues through a combination of organic growth and strategic acquisitions. In this new phase alongside AltamarCAM, the company will continue pursuing the organic and inorganic growth strategy initiated in 2020, which has enabled it to triple sales and accelerate its international expansion through acquisitions in Canada, Spain, and most recently Finland.
At the same time, Labomar will continue investing in its production and logistics infrastructure while expanding its product portfolio and international footprint. In this regard, Nicola Zambon, CEO and Founder of Cleon Capital, commented: “We are proud to have the support of AltamarCAM, which joins an established group of more than 100 successful entrepreneurial families and 20 international institutional investors who have placed their trust in us and support the development of our business projects.”
In 2020, Cleon Capital led a group of Italian investors in acquiring a stake in the company and acted as anchor investor during its IPO. Subsequently, in 2023, UK-based Charterhouse led a public takeover bid supported by Labomar’s founder and Cleon Capital investors to drive a new phase of expansion. In 2024, Cleon Capital supported Labomar’s management team in the acquisition of Spanish company Laboratorios Entema, backing the growth and internationalization plan promoted by Charterhouse, which recently culminated in the acquisition of Finnish nutraceutical company Pharmia.
About AltamarCAM Partners
AltamarCAM Partners is a global private markets investment firm whose core objective is to provide institutional investors—including insurance companies, pension funds, and financial institutions—as well as high-net-worth private clients with efficient access to private markets investments across private equity, venture capital, real assets (real estate and infrastructure), and private debt/credit. The firm achieves this through the selection of leading international managers and a range of investment strategies, including primary funds, secondary transactions, co-investments, and direct investments.
In addition, the AltamarCAM Group provides independent investment banking and merchant banking services through its subsidiary Altamar Advisory Partners, while also offering direct and efficient access to funds managed by a selected group of international asset managers.
With offices in Madrid, Cologne, Barcelona, New York, London, Santiago de Chile, and Munich, the firm employs approximately 300 professionals. AltamarCAM Partners manages nearly €22 billion of capital committed by investors.
About Cleon Capital
Cleon Capital is an independent investment and advisory firm that partners with international investors, executives, and entrepreneurs to accelerate the growth of high-potential companies based in Southern Europe. The firm provides solutions combining flexible capital, an international network, long-term strategic vision, and extensive experience in both organic and acquisition-driven corporate development.
Its investor base includes nearly 100 successful entrepreneurs, high-net-worth individuals, family offices, and international institutional investors.
Cleon Capital’s current portfolio includes leading European companies such as Lexer Group, Spain’s leading alternative legal services provider; Labomar, a specialist in the research and production of food supplements, nutritional products, and medical devices; Gias, an Italian market leader in frozen plant-based ready meals; and ABK Group, a manufacturer of premium ceramic surfaces and invisible induction solutions for modern kitchens.
Among its most notable success stories is Hevo Group, a buy-and-build project exited in 2024 that became Spain’s largest shell egg producer, generating revenues of more than €150 million.
cloud technology axon
The transaction brings together two highly complementary hospitality t...
